# Comparative study between the use of intravascular ultrasound versus conventional venography in management of iliofemoral chronic venous insufficiency

Mahmoud F.M. Ashour<sup>a</sup>, Abd El Rahman M. Ahmed<sup>b</sup>, Amr N. Kamel<sup>b</sup>, Sherif M. Essam Eldin<sup>b</sup>, Ahmed M. SaadEldin<sup>b</sup>, Mohamed M. Mohamed Zaki<sup>b</sup>

<sup>a</sup>Department of Vascular Surgery, Egypt Air Hospital, <sup>b</sup>Department of Vascular Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence to Mahmoud F.M. Ashour, MMSc, Flat 8 ,69 Building, The First Neighborhood, Seventh Zone, Sherouk City. Postal Code 11836. e-mail: mfashour8@hotmail.com

Received: 25 September 2020 Revised: 10 October 2020 Accepted: 10 October 2020 Published: 18 May 2021

The Egyptian Journal of Surgery 2021, 40:140–152

#### Objective

The current study was carried out to reveal the added value of intravascular ultrasound (IVUS) in the diagnosis, clinical decision, and subsequent outcomes of the treatment of iliofemoral chronic venous insufficiency, relative to contrast multiplanar venography.

#### Patients and methods

This is a prospective randomized study encompassing 40 patients with symptomatic chronic venous insufficiency. Patients were randomly stratified into two groups; 20 patients were randomized into exclusively having multiplanar venography, and the other group would have IVUS in addition to completion venography to guide the intervention.

#### Results

Both the duration of the procedure and amount of contrast injected were significantly higher in the venography group (P=0.014 and P<0.0001, respectively). Postoperative creatinine was significantly less in the IVUS group (P<0.0001), and the mean increase in serum creatinine was significantly higher in the venography group (P<0.0001). Target lesion revascularization was significantly higher in the venography group (P=0.002).

IVUS detected a mean of 2.75 significant lesions compared with a mean of 1.6 lesions detected through venography (P<0.001) and was more able to detect stenoses and occlusions than computed tomography venography during follow-up, with a P value of 0.018. IVUS group showed a statistically significant higher primary assisted patency rate compared with venography, with a P value of 0.017. **Conclusion** 

IVUS is one of the most effective tools in the armamentarium of a vascular surgeon and interventionalist, especially when dealing with venous disorders. Our study suggests that as an imaging modality, it provides more sensitive and accurate details of the lesion, aids in setting a more appropriate plan, guides the surgeon through a more precise sizing and deployment of the necessary stents, and finally, provides a better follow-up tool to detect and guide subsequent interventions, resulting in higher primary assisted and secondary patency rates.

#### Keywords:

intravascular ultrasound, postthrombotic syndrome, venoplasty

Egyptian J Surgery 40:140–152 © 2021 The Egyptian Journal of Surgery 1110-1121

# Introduction

Deep vein thrombosis (DVT) is a major health care risk causing fatal short-term complications as well as grave long-term effects. It affects approximately two patients per 1000 population, and results in postthrombotic syndrome (PTS) in 0-50% of patients even if patients received the optimal anticoagulant therapy [1,2].

PTS manifests as a spectrum of symptoms and signs of chronic venous insufficiency (CVI) that can impose significant morbidity and have a negative effect on quality of life. Chronic venous hypertension caused by a combination of residual venous obstruction and valvular reflux is believed to play a major role in the pathophysiology of PTS [2]. Patients with iliofemoral DVT managed conservatively with anticoagulation therapy and compression stockings have a high risk of PTS. Less than half of these patients regain iliofemoral patency, which is a main predictor for the development of PTS, and subsequently signs and symptoms of CVI [3]. Management of CVI is difficult and the key for successful treatment is proper diagnosis, which mainly depends on proper imaging.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Venography has been widely used to diagnose venous obstruction. Evidence of obstruction using venography includes abundance of collaterals, pancaking, parrot beak appearance, and venous dilatation proximal to obstruction. However, degree of sensitivity of venography has been reported to vary greatly according to the site of obstruction or stenosis [4].


Intravascular ultrasound (IVUS) has been emerging as a more informative diagnostic tool when it comes to detecting areas and degrees of stenosis compared with multiplanar venography owing to its ability to identify and measure the cross-sectional area and degree of stenosis in the often irregular and noncircular venous lumen [5].

## Patients and methods

This is a prospective randomized study encompassing 40 patients with symptomatic CVI starting June 2016 till June 2020 in Ain Shams University Hospitals and Egypt Air Hospital. Patients were randomly stratified through a computer-generated randomization pattern into two groups: 20 patients were randomized into exclusively having multiplanar venography to guide venoplasty, where the three planes were anteroposterior, 30 degree left anterior oblique, and 30 degree right anterior oblique projections (venography group), and the other group would have IVUS in addition to completion venography to guide the intervention (IVUS group) (Fig. 1). All participating patients had to sign an informed consent, and ethical committee approval from Ain Shams University ethical committee was obtained before initiation of the study. Patients who fulfilled the inclusion criteria (Table 1) had venoplasty performed for CVI, with recording of number and types of lesions, need for stent placement, number of stent deployed, operation time, amount of contrast, and technical success using the different imaging modalities. In all patients undergoing stenting of the iliac vein owing to compression, the proximal stent was placed protruding in the IVC [6] (Tables 2–4).

Stenosis was considered significant if more than 50% than the luminal diameter in venography or surface area in IVUS. In all patients who underwent stenting for PTS, the whole iliac venous axis was covered by stents from the IVC crossing the inguinal ligament preserving the profunda vein, and when multiple stents were used, an overlap of at least 1 cm was maintained between each stent and the other [7]. Stent sizing was done through measurement of the dimeter of the reference vessel (most proximal unaffected vein segment of normal diameter) using preoperative computed tomography (CT)venography in

#### Figure 1



Kaplan-Meier curve showing assisted primary patency.

#### Table 1 Inclusion and exclusion criteria

| Inclusion criteria  | Exclusion criteria  |
|---|---|
| 1. Patient must be above 18 years of age                            | 1. Refusal to sign the consent and participate in the study   |
| 2. Willing to participate in the study                              | 2. Active malignancy  |
| 3. Previous history of at least a single documented iliofemoral DVT | 3. Renal impairment with persistently elevated serum creatinine level                                   |
| 4. Class 4, 5, or 6 in CEAP classification [11]                     | 4. Acute deep venous thrombosis   |
|   | 5. Known allergy to iodinated contrast  |
|   | 6. Pregnancy either during recruitment or presence of an intent for pregnancy during the study duration |
|   | 7. Known thrombophilia  |
|   | 8. Previous venous surgery or venoplasty with or without stenting                                       |

DVT, deep vein thrombosis.

#### Table 2 Association of preoperative Duplex study between intravascular ultrasound and venography groups

|   | Group  |            |                    |
|---|--------|------------|--------------------|
|   | IVUS   | Venography | P value            |
| Preoperative duplex lesion type                       |        |            |                    |
| Stenosis  | 9      | 5          | 0.4**              |
|   | 64.3%  | 35.7%      |                    |
| Occlusion   | 10     | 14         |                    |
|   | 41.7%  | 58.3%      |                    |
| NAD   | 1      | 1          |                    |
|   | 50.0%  | 50.0%      |                    |
| Common iliac vein                                     | 2      | 0          |                    |
|   | 100.0% | 0.0%       |                    |
| External iliac vein                                   | 3      | 2          |                    |
|   | 60.0%  | 40.0%      |                    |
| Common femoral vein                                   | 5      | 5          |                    |
|   | 50.0%  | 50.0%      |                    |
| Preoperative duplex lesion site                       |        |            |                    |
| Common and external iliac veins                       | 0      | 5          | 0.115 <sup>*</sup> |
|   | 0.0%   | 100.0%     |                    |
| Common iliac, external iliac, and common femoral vein | 2      | 2          |                    |
|   | 50.0%  | 50.0%      |                    |
| External iliac vein and common femoral vein           | 7      | 5          |                    |
|   | 58.3%  | 41.7%      |                    |
| NAD   | 1      | 1          |                    |
|   | 50.0%  | 50.0%      |                    |

IVUS, intravascular ultrasound. \*P-value calculated using Chi square test. \*\*P-value calculated using Liklihood ratio.

venography group, and reference vessel surface area using IVUS in IVUS group. Postoperatively, patients were kept on antiplatelets and class II compression stockings and assessed serially using the venous clinical severity scoring (VCSS) in addition to venous duplex on 3 monthly basis. For those who presented with restenosis, only CT venography was done in the venography group, and both CT venography and IVUS were done in the IVUS group. Primary end point was comparing number of lesions detected through IVUS with those detected through venography in the IVUS group [8].

Secondary end points included technical success and reintervention rates between the IVUS and venography groups.

## Results

In total, 40 patients were enrolled in this study. There were no mortalities among the patients, and the followup duration was 18 months. Mean age was 47 years (SD 8), 29 (72.5%) patients were males, 31 (77.5%) were diabetics, mean number of days since last DVT was 236 days (SD 54), and mean VCSS was 19 initially, and 14, 9, 7, and 5 at 1, 3, 6, and 12 months, respectively. Preoperative duplex showed stenosis in 14 (35%) lesions, occlusion in 24 (60%) lesions and no significant stenosis or occlusion in two (5%) lesions. Lesions were most situated in the external iliac and common femoral vein (30%), then isolated common femoral vein (25%), then equally in common and external iliac veins and external iliac vein alone

|                                | Group     |             |                   |
|--------------------------------|-----------|-------------|-------------------|
|                                | IVUS      | Venography  | P value           |
| Venous claudication            |           |             |                   |
| Yes                            | 20        | 20          | _                 |
|                                | 50.0%     | 50.0%       |                   |
|                                | 20        | 20          |                   |
|                                | 50.0%     | 50.0%       |                   |
| Pigmentation                   |           |             |                   |
| No                             | 11        | 10          | 0.75 <sup>*</sup> |
|                                | 52.4%     | 47.6%       |                   |
| Yes                            | 9         | 10          |                   |
|                                | 47.4%     | 52.6%       |                   |
| Venous ulcer                   |           |             |                   |
| No                             | 17        | 16          | 0.5**             |
|                                | 51.5%     | 48.5%       |                   |
| Yes                            | 3         | 4           |                   |
|                                | 42.9%     | 57.1%       |                   |
| Associated peripheral ischemia |           |             | **                |
| No                             | 19        | 18          | 0.5**             |
|                                | 51.4%     | 48.6%       |                   |
| Yes                            | 1         | 2           |                   |
|                                | 33.3%     | 66.7%       |                   |
| Pain                           |           |             |                   |
| Daily                          | 8         | 8           | 1                 |
|                                | 50.0%     | 50.0%       |                   |
| Daily with medication          | 12        | 12          |                   |
|                                | 50.0%     | 50.0%       |                   |
| Varicose veins                 |           |             | **                |
| Absent                         | 4         | 3           | 0.76**            |
| _                              | 57.1%     | 42.9%       |                   |
| Few                            | 12        | 10          |                   |
|                                | 54.5%     | 45.5%       |                   |
| Multiple                       | 3         | 5           |                   |
| Futureine                      | 37.5%     | 62.5%       |                   |
| Extensive                      | 1         | 2<br>66.7%  |                   |
| Vanaua adama                   | 33.3%     | 66.7%       |                   |
| Venous edema                   | 0         | 1           | 0.35**            |
| Evening only                   | 0         | 1           | 0.35              |
| Afternoon                      | 0.0%<br>5 | 100.0%<br>7 |                   |
| Alternoon                      | 41.7%     | 58.3%       |                   |
| Morning                        | 15        | 12          |                   |
| Morning                        | 55.6%     | 44.4%       |                   |
| Pigmentation                   | 33.078    | 44.470      |                   |
| None                           | 11        | 9           | 0.83**            |
| None                           | 55.0%     | 45.0%       | 0.00              |
| Limited and old                | 1         | 1           |                   |
|                                | 50.0%     | 50.0%       |                   |
| Diffuse and more recent        | 6         | 6           |                   |
|                                | 50.0%     | 50.0%       |                   |
| Wide and recent                | 2         | 4           |                   |
|                                | 33.3%     | 66.7%       |                   |
| Inflammation                   | 00.070    | 00.770      |                   |
| None                           | 8         | 7           | 0.29**            |
| -                              | 53.3%     | 46.7%       | 0.20              |
| Mild cellulitis                | 4         | 8           |                   |
|                                | 33.3%     | 66.7%       |                   |
|                                | 00.070    |             | (Continued)       |

Table 3 Association of preoperative medications and presenting symptoms between intravascular ultrasound and venography groups

#### Table3 (Continued)

|                              | Group  |            |         |
|------------------------------|--------|------------|---------|
|                              | IVUS   | Venography | P value |
| Moderate cellulitis          | 6      | 2          |         |
|                              | 75.0%  | 25.0%      |         |
| Severe cellulitis            | 2      | 3          |         |
|                              | 40.0%  | 60.0%      |         |
| nduration                    |        |            |         |
| None                         | 13     | 10         | 0.53**  |
|                              | 56.5%  | 43.5%      |         |
| Focal <5 cm                  | 4      | 3          |         |
|                              | 57.1%  | 42.9%      |         |
| <1/3 gaiter                  | 2      | 5          |         |
| -                            | 28.6%  | 71.4%      |         |
| >1/3 gaiter                  | 1      | 2          |         |
| 0                            | 33.3%  | 66.7%      |         |
| ctive ulcers                 |        |            |         |
| None                         | 17     | 16         | 0.7**   |
|                              | 51.5%  | 48.5%      |         |
| 1                            | 2      | 2          |         |
|                              | 50.0%  | 50.0%      |         |
| 2                            | 0      | 1          |         |
|                              | 0.0%   | 100.0%     |         |
| >2                           | 1      | 1          |         |
| · -                          | 50.0%  | 50.0%      |         |
| llcer duration               |        |            |         |
| None                         | 17     | 16         | 0.49**  |
|                              | 51.5%  | 48.5%      | 0110    |
| <3 months                    | 0      | 1          |         |
|                              | 0.0%   | 100.0%     |         |
| 3–12 months                  | 3      | 3          |         |
|                              | 50.0%  | 50.0%      |         |
| Jlcer size                   |        |            |         |
| None                         | 17     | 16         | 1.4**   |
|                              | 51.5%  | 48.5%      |         |
| 2–6 cm                       | 3      | 3          |         |
|                              | 50.0%  | 50.0%      |         |
| >6 cm                        | 0      | 1          |         |
|                              | 0.0%   | 100.0%     |         |
| Compression therapy          | 0.070  | 100.070    |         |
| Intermittent                 | 5      | 3          | 0.72**  |
| internation                  | 62.5%  | 37.5%      | 0.72    |
| Most days                    | 8      | 9          |         |
| woot days                    | 47.1%  | 52.9%      |         |
| Fully compliant              | 7      | 8          |         |
|                              | 46.7%  | 53.3%      |         |
| Preoperative anticoagulation | -0.770 | 00.076     |         |
| No                           | 15     | 16         | 0.7**   |
|                              | 48.4%  | 51.6%      | 0.7     |
| Yes                          | 40.4%  | 4          |         |
| 100                          | 55.6%  | 44.4%      |         |

IVUS, intravascular ultrasound. \*P-value calculated using Chi square test. \*\*P-value calculated using Liklihood ratio.

(12.5% each), and least frequently, the whole iliofemoral segment (10%) (Tables 5–8).

There were no statistically significant differences between baseline clinical data and laboratory investigations in the two groups, with the exception of a statistically significant higher level of glycated hemoglobin in the venography group (P=0.03). Both the duration of the procedure and amount of contrast injected were significantly higher in the

|   | Group |            |         |
|---|-------|------------|---------|
|   | IVUS  | Venography | P value |
| Guidewire                               |       |            |         |
| Standard                                | 9     | 8          | 0.8**   |
|   | 52.9% | 47.1%      |         |
| Standard+superstiff amplatz             | 10    | 10         |         |
|   | 50.0% | 50.0%      |         |
| Standard+superstiff amplatz+0.018 stiff | 1     | 2          |         |
|   | 33.3% | 66.7%      |         |
| Balloon diameter                        |       |            |         |
| 12                                      | 0     | 1          | 0.65**  |
|   | 0.0%  | 100.0%     |         |
| 14                                      | 8     | 7          |         |
|   | 53.3% | 46.7%      |         |
| 16                                      | 7     | 8          |         |
|   | 46.7% | 53.3%      |         |
| 18                                      | 5     | 4          |         |
|   | 55.6% | 44.4%      |         |
| Type of stents                          |       |            |         |
| Zilver Vena (COOK medical)              | 13    | 9          | 0.2*    |
|   | 59.1% | 40.9%      |         |
| WALLSTENT (Boston Scientific)           | 7     | 11         |         |
|   | 38.9% | 61.1%      |         |
| Procedure-related adverse events        |       |            |         |
| No                                      | 19    | 15         | 0.06**  |
|   | 55.9% | 44.1%      |         |
| Yes                                     | 1     | 5          |         |
|   | 16.7% | 83.3%      |         |

IVUS, intravascular ultrasound. \*P-value calculated using Chi square test. \*\*P-value calculated using Liklihood ratio.

| Table 5 | Background | medical | data | for | the | whole | study |
|---------|------------|---------|------|-----|-----|-------|-------|
| populat | ion        |         |      |     |     |       |       |

|                          | n (%)     |
|--------------------------|-----------|
| Sex                      |           |
| Male                     | 29 (72.5) |
| Female                   | 11 (27.5) |
| Smoking                  |           |
| No                       | 17 (42.5) |
| Yes                      | 23 (57.5) |
| Obesity                  |           |
| No                       | 27 (67.5) |
| Yes                      | 13 (32.5) |
| Diabetes                 |           |
| No                       | 31 (77.5) |
| Yes                      | 9 (22.5)  |
| Hypertension             |           |
| No                       | 27 (67.5) |
| Yes                      | 13 (32.5) |
| Hypercholesterolemia     |           |
| No                       | 29 (72.5) |
| Yes                      | 11 (27.5) |
| ISHD previous stroke     |           |
| No                       | 40 (100)  |
| No                       | 40 (100)  |
| Chronic renal impairment |           |
| No                       | 40 (100)  |

venography (P=0.014)and *P*<0.0001, group respectively) (Tables 9-12). Preoperative lesion site and type were not found to be statistically significant between the two groups, with a *P* value of 0.12 and 0.4, respectively, which excludes lesion characteristics from being a confounding factor despite randomization. Postoperative creatinine was significantly less in the IVUS group with a mean of 1.014 mg/dl (*P*<0.0001), and the mean increase in serum creatinine was 0.059 mg/dl in IVUS group and 0.242 in venography group, and this was statistically significant (P<0.0001), which means that IVUS leads to less contrast injection and less renal affection (Tables 13 and 14).

On comparing outcome between the two groups, target lesion revascularization was significantly higher in venography group, with a P value of 0.002, and although there was an overall statistically significant improvement in VCSS in both groups, it was more obvious and significant in the IVUS group compared with the venography group at 6- and 12-month follow-up (P=0.021 and 0.03, respectively) (Tables 15 and 16, 13).

 Table 6 Preoperative baseline investigations for the whole study population

|            | Mean   | SD    |
|------------|--------|-------|
| TLC        | 13 500 | 3200  |
| PLT        | 373    | 65    |
| CRP        | 54.2   | 29    |
| ESR        | 79.12  | 34.74 |
| HBA1C      | 5.08   | 0.54  |
| Creatinine | 0.89   | 0.26  |
| BUN        | 12.625 | 5.85  |
| ALT        | 19.12  | 5.5   |
| AST        | 25.5   | 5.75  |
| PT         | 30.7   | 28.5  |
| PTT        | 36.3   | 34.5  |
| INR        | 1.25   | 0.097 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HBA1C, glycated hemoglobin; INR, international normalized ratio; PLT, platelet; PT, prothrombin time; PTT, partial thromboplastin time; TLC, total leukocyte count.

#### Table 7 Preoperative imaging and presenting symptoms for the whole study population

| , , ,   |              |
|---|--------------|
|   | n (%)        |
| Preoperative duplex lesion type                       |              |
| Stenosis  | 14 (35)      |
| Occlusion   | 24 (60)      |
| NAD   | 2 (5)        |
| Preoperative duplex lesion site                       |              |
| Common iliac vein                                     | 2 (5)        |
| External iliac vein                                   | 5 (12.5)     |
| Common femoral vein                                   | 10 (25)      |
| Common and external iliac veins                       | 5 (12.5)     |
| Common iliac, external iliac, and common femoral vein | 4 (10)       |
| External iliac vein and common femoral vein           | 12 (30)      |
| NAD   | 2 (5)        |
| Diagnostic IVUS                                       |              |
| No  | 20 (50)      |
| Yes   | 20 (50)      |
| Venous claudication                                   |              |
| Yes   | 40 (100)     |
| Pigmentation  |              |
| No  | 21           |
|   | (52.5)       |
| Yes   | 19           |
|   | (47.5)       |
| Venous ulcer  |              |
| No  | 33<br>(82.5) |
| Yes   | 7 (17.5)     |
| Associated peripheral ischemia                        | 7 (17.3)     |
| No  | 37           |
| NO  | (92.5)       |
| Yes   | 3 (7.5)      |
| Pain  | - ( - )      |
| Daily   | 16 (40)      |
| Daily with medication                                 | 24 (60)      |
| Varicose veins  | ( - )        |
| Absent  | 7 (17.5)     |
|   | (Continued)  |
|   |              |

#### Table 7 (Continued)

|                         | n (%)             |
|-------------------------|-------------------|
| Few                     | 22 (55)           |
| Multiple                | 8 (20)            |
| Extensive               | 3 (7.5)           |
| Venous edema            |                   |
| Evening only            | 1 (2.5)           |
| Afternoon               | 12 (30)           |
| Morning                 | 27                |
|                         | (67.5)            |
| Pigmentation            |                   |
| None                    | 20 (50)           |
| Limited and old         | 2 (5)             |
| Diffuse and more recent | 12 (30)           |
| Wide and recent         | 6 (15)            |
| Inflammation            |                   |
| None                    | 15                |
|                         | (37.5)            |
| Mild cellulitis         | 12 (30)           |
| Moderate cellulitis     | 8 (20)            |
| Severe cellulitis       | 5 (12.5)          |
| None                    | 23                |
| None                    | (57.5)            |
| Focal <5 cm             | 7 (17.5)          |
| <1/3 gaiter             | 7 (17.5)          |
| >1/3 gaiter             | 3 (7.5)           |
| Active ulcers           |                   |
| None                    | 33                |
|                         | (82.5)            |
| 1                       | 4 (10)            |
| 2                       | 1 (2.5)           |
| >2                      | 2 (5)             |
| Ulcer duration          |                   |
| None                    | 33                |
|                         | (82.5)            |
| <3 months               | 1 (2.5)           |
| 3–12 months             | 6 (15)            |
| Ulcer size              |                   |
| None                    | 33                |
|                         | (82.5)            |
| 2–6 cm                  | 6 (15)<br>1 (2 5) |
| >6 cm                   | 1 (2.5)           |

IVUS, intravascular ultrasound.

)

Regarding evaluating the diagnostic ability of IVUS to detect significant lesions compared with conventional venography in the IVUS group (where both IVUS and venography were done), IVUS was found to be significantly superior than venography, being able to diagnose a mean of 2.75 significant lesions (SD 0.79) compared with a mean of 1.6 lesions through venography (SD 0.76), which was found to be statistically significant, with a P value of less than 0.0001 (Table 5). Moreover, IVUS was more able to detect stenoses and occlusions than CT venography during follow-up, with a P value of .018 (Tables 17 and 10).

#### Table 8 Follow-up venous clinical severity scoring

|                                  | Mean   | SD   |
|----------------------------------|--------|------|
| VCSS                             | 20     | 6    |
| VCSS at 1 month                  | 14     | 4    |
| VCSS at 3 months                 | 9      | 3    |
| VCSS at 6 months                 | 7      | 2    |
| Ulcer healing duration in months | 4.7    | 2.25 |
|                                  | Median | IQR  |
| VCSS at 12 months                | 5      | 5    |
| Time to TLR in months            | 9      | 17   |
|                                  |        |      |

TLR, target lesion revascularization; VCSS, venous clinical severity scoring.

On exploring the patency using Kaplan–Meier curve, IVUS groups showed a statistically significant higher primary assisted patency rate compared with venography, with a *P* value of 0.017 (Fig. 1).

## Discussion

The evidence summarized in the current study brings to light that IVUS added extremely pivotal information, principally regarding the number, pattern, and types of vascular lesions within the venous system that represented a major challenge in dealing with CVI. Such advantages made it a valuable diagnostic tool for evaluating the extent and severity of iliofemoral CVI. Employment of such findings in the health care systems will reflect considerably on the short-term and long-term outcomes.

Accurate identification and reliable measurement of the extent and severity of venous lesions is of utmost importance and critical need for vascular surgeons. In the present study, the mean number of lesions which were recognized by IVUS was significantly higher than venography. Precisely, IVUS succeeded in the detection of 23 lesions, which were not detectable based on multiplanar venography alone. Moreover, IVUS identified six occlusive lesions, which were lesions based distinguished as stenotic on venography. This information allowed a precise adaptation of the treatment plan, giving each patient the safest, effective, and appropriate intervention.

The findings in our study are consistent with numerous studies such as the VIDIO (venography vs. IVUS for diagnosing and treating iliofemoral vein obstruction) trial, where both IVUS and multiplanar venography were performed to 100 patients. The investigators found that venography successfully detected 51 lesions compared with 81 lesions detected by IVUS, in addition to the underestimation of the severity of lesions in venography by 11% compared with IVUS (P<0.001) [9].

# Table 9 Association of background medical data betweenintravascular ultrasound and venography groups

|                   | Group              |            |                   |
|-------------------|--------------------|------------|-------------------|
|                   | IVUS               | Venography | P value           |
| Sex               |                    |            |                   |
| Male              | 17                 | 12         | 0.077*            |
|                   | 58.6%              | 41.4       |                   |
| Female            | 3                  | 8          |                   |
|                   | 27.3%              | 72.7%      |                   |
| Smoking           |                    |            |                   |
| No                | 7                  | 10         | 0.34*             |
|                   | 41.2%              | 58.8%      |                   |
| Yes               | 13                 | 10         |                   |
|                   | 56.5%              | 50%        |                   |
| Obesity           |                    |            |                   |
| No                | 16                 | 11         | 0.091*            |
|                   | 59.3%              | 40.7%      |                   |
| Yes               | 4                  | 9          |                   |
|                   | 30.8%              | 69.2%      |                   |
| Diabetes          |                    |            |                   |
| No                | 18                 | 13         | 0.05**            |
|                   | 58.1%              | 41.9%      |                   |
| Yes               | 2                  | 7          |                   |
|                   | 22.2%              | 77.8%      |                   |
| Hypertension      |                    |            |                   |
| No                | 15                 | 12         | 0.31 <sup>*</sup> |
|                   | 55.6%              | 44.4%      |                   |
| Yes               | 5                  | 8          |                   |
|                   | 38.5%              | 61.5%      |                   |
| Hypercholester    | olemia             |            |                   |
| No                | 16                 | 13         | 0.28*             |
|                   | 55.2%              | 44.8%      |                   |
| Yes               | 4                  | 7          |                   |
|                   | 36.4%              | 63.6%      |                   |
| Recurrent DVT     |                    |            |                   |
| No                | 13                 | 12         | 0.74 <sup>*</sup> |
|                   | 52%                | 48%        |                   |
| Yes               | 7                  | 8          |                   |
|                   | 46.7%              | 53.3%      |                   |
| DV/T de contra la | demonstration 1870 | 10         |                   |

DVT, deep vein thrombosis; IVUS, intravascular ultrasound. \**P*-value calculated using Chi square test. \*\**P*-value calculated using Liklihood ratio.

This fact was acknowledged by Lau and colleagues who investigated the means of improving the sensitivity of venography in detection and assessment of lesions by relying on multiple venographic findings, including collaterals, pancaking, and contrast thinning in venography, and comparing them with IVUS. Despite their promising findings, they concluded that although anteroposterior venography can indirectly diagnose venous obstruction, they still recommended the use of IVUS owing to the better sensitivity and more precise intervention planning [4].

It is important to emphasize that patients within multiplanar venography were subjected to a

| Table 10 Comparing mean vales of background medi | ical data between the two groups |
|--|----------------------------------|
|--|----------------------------------|

|                               | Group      | Ν  | Mean    | SD      | P value** | Difference |
|-------------------------------|------------|----|---------|---------|-----------|------------|
| Age                           | IVUS       | 20 | 45.45   | 11.852  | 0.144     | -5.750     |
|                               | Venography | 20 | 51.20   | 12.484  |           |            |
| Number of days since last DVT | IVUS       | 20 | 390.50  | 673.236 | 0.361     | 141.500    |
|                               | Venography | 20 | 249.00  | 59.639  |           |            |
| TLC                           | IVUS       | 20 | 10.050  | 2.8419  | 0.598     | -0.5000    |
|                               | Venography | 20 | 10.550  | 3.0946  |           |            |
| PLT                           | IVUS       | 20 | 285.850 | 87.6208 | 0.652     | -11.5500   |
|                               | Venography | 20 | 297.400 | 72.0266 |           |            |
| CRP                           | IVUS       | 20 | 21.165  | 23.4785 | 0.812     | -1.9450    |
|                               | Venography | 20 | 23.110  | 27.6944 |           |            |
| ESR                           | IVUS       | 20 | 36.600  | 28.5480 | 0.866     | -1.7000    |
|                               | Venography | 20 | 38.300  | 34.4935 |           |            |
| HBA1C                         | IVUS       | 20 | 5.105   | 1.1741  | 0.033     | -1.0000    |
|                               | Venography | 20 | 6.105   | 1.6363  |           |            |
| Creatinine                    | IVUS       | 20 | 0.955   | 0.2010  | 0.519     | -0.0420    |
|                               | Venography | 20 | 0.997   | 0.2073  |           |            |
| BUN                           | IVUS       | 20 | 12.800  | 4.3237  | 0.040     | -3.2000    |
|                               | Venography | 20 | 16.000  | 5.1504  |           |            |
| ALT                           | IVUS       | 20 | 15.850  | 4.6597  | 0.650     | -0.7500    |
|                               | Venography | 20 | 16.600  | 5.6606  |           |            |
| AST                           | IVUS       | 20 | 18.850  | 6.8154  | 0.261     | -2.3605    |
|                               | Venography | 19 | 21.211  | 6.0789  |           |            |
| PT                            | IVUS       | 20 | 28.750  | 4.4352  | 0.576     | 0.8000     |
|                               | Venography | 20 | 27.950  | 4.5245  |           |            |
| РТТ                           | IVUS       | 20 | 33.200  | 5.1360  | 0.873     | 0.2500     |
|                               | Venography | 20 | 32.950  | 4.7069  |           |            |
| INR                           | IVUS       | 20 | 1.125   | 0.2025  | 0.770     | 0.0170     |
|                               | Venography | 20 | 1.108   | 0.1600  |           |            |
|                               | Venography | 20 | 2.35    | 0.875   |           |            |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HBA1C, glycated hemoglobin; INR, international normalized ratio; PLT, platelet; PT, prothrombin time; PTT, partial thromboplastin time; TLC, total leukocyte count. \*\*P value calculated using independent samples *t* test.

| Table 11 | Comparing mean | vales of intraopera | ative details betwee | n the two aroups |
|----------|----------------|---------------------|----------------------|------------------|
|          |                |                     |                      |                  |

|                                  | Group      | Ν  | Mean   | SD     | P value** | Mean difference |
|----------------------------------|------------|----|--------|--------|-----------|-----------------|
| Largest sheath diameter          | IVUS       | 20 | 8      | 2      | 0.471     | 0.350           |
|                                  | Venography | 20 | 8      | 1      |           |                 |
| Number of stents deployed        | IVUS       | 20 | 2.35   | 0.587  | 0.768     | 0.050           |
|                                  | Venography | 20 | 2.30   | .470   |           |                 |
| Amount of contrast injected (ml) | IVUS       | 20 | 33.50  | 10.400 | 0.000     | -103.500        |
|                                  | Venography | 20 | 137.00 | 20.026 |           |                 |
| Duration of the procedure (min)  | IVUS       | 20 | 111.50 | 35.433 | 0.014     | -27.500         |
|                                  | Venography | 20 | 139.00 | 31.937 |           |                 |

IVUS, intravascular ultrasound. \*\*P value calculated using independent samples t test.

considerably higher dose of radiation and contrast (mean of 137 ml), relative to those within IVUS group (mean of 35.5 ml, P=0.035). This is because, the appropriate demonstration of venous lesions necessitated good concentration of the contrast material in addition to more frequent subtraction angiographies from different angles. This finding was reflected on the kidney functions in the long-term outcomes. Despite being within normal range preoperatively, the mean level of creatine was

significantly higher among patients diagnosed with venography postoperatively.

It should also be mentioned that the procedure duration was significantly shorter among patients within the IVUS group in comparison with patients within the venography group. Given the limited diagnostic capability of venography and related risks, using IVUS decreased the exposure to radiation and contrast volume besides being an accurate diagnostic tool.

Moon difforonco

| Table 12 Comparing mean vales of venous clinical severity scoring score between the two groups |       |   |      |    |                       |
|--|-------|---|------|----|-----------------------|
|  | Group | Ν | Mean | SD | P value <sup>**</sup> |
|  |       |   |      |    |                       |

|                   | Group      | IN | Iviean | 5D | P value | Mean difference |
|-------------------|------------|----|--------|----|---------|-----------------|
| Baseline VCSS     | IVUS       | 20 | 12     | 5  | 0.515   | -1.100          |
|                   | Venography | 20 | 13.00  | 6  |         |                 |
| VCSS at 1 month   | IVUS       | 20 | 8      | 3  | 0.175   | -1.650          |
|                   | Venography | 20 | 10     | 4  |         |                 |
| VCSS at 3 months  | IVUS       | 20 | 6      | 2  | 0.129   | -1.150          |
|                   | Venography | 20 | 7      | 3  |         |                 |
| VCSS at 6 months  | IVUS       | 20 | 5      | 1  | 0.021   | -1.450          |
|                   | Venography | 20 | 6      | 2  |         |                 |
| VCSS at 12 months | IVUS       | 20 | 5      | 2  | 0.035   | -1.700          |
|                   | Venography | 20 | 6      | 3  |         |                 |

IVUS, intravascular ultrasound; VCSS, venous clinical severity scoring. \*\*P value calculated using independent samples t test.

Table 13 Comparing mean values of preoperative and postoperative serum creatinine in both groups

|                          | Group      | Ν  | Mean  | SD     | P value** |
|--------------------------|------------|----|-------|--------|-----------|
| Preoperative creatinine  | IVUS       | 20 | 0.955 | 0.2010 | 0.519     |
|                          | Venography | 20 | 0.997 | 0.2073 |           |
| Postoperative creatinine | IVUS       | 20 | 1.014 | 0.1940 | < 0.0001  |
|                          | Venography | 20 | 1.239 | 0.1565 |           |

IVUS, intravascular ultrasound. \*\*P value calculated using independent sample t test.

#### Table 14 Comparing mean vales of follow up data between the 2 groups

|                                 | •          |    | • •   |                |           |                 |
|---------------------------------|------------|----|-------|----------------|-----------|-----------------|
|                                 | Group      | Ν  | Mean  | Std. deviation | P-value** | Mean difference |
| Time to TLR in months           | IVUS       | 20 | 3.15  | 6.115          |           |                 |
|                                 | Venography | 20 | 24.10 | 68.070         | .186      | -20.950         |
| Ulcer healing duration inMonths | IVUS       | 3  | 3.33  | 1.528          |           |                 |
|                                 | Venography | 5  | 5.60  | 2.302          | .147      | -2.267          |
| Post-operative creatinine       | IVUS       | 20 | 1.014 | .1940          |           |                 |
|                                 | Venography | 20 | 1.239 | .1565          | .000      | 2250            |
|                                 |            |    |       |                |           |                 |

It is pivotal to put into consideration the imperative role of clinical assessment, patient history, and radiological findings all together before the individualization of the treatment plan. In addition, the role of multiplanar venography in the management plan of iliofemoral CVI cannot be neglected. Venography remains a desirable adjunct in iliac vein stenting, as it allows a panoramic view of the pathologic process, particularly the collaterals. Moreover, IVUS may provide a partial image of particular lesions, principally those situated at the iliac-caval confluences, and therefore, the role of venography cannot be completely omitted [10].

The long-term outcomes of iliofemoral CVI necessitated the move toward a more meticulous identification and treatment method for venous pathologies. In this study, patients within the venography group experienced fivefolds more procedure-related adverse events compared with IVUS. Moreover, after the first postoperative 12 months, 45% within the venography group had residual venous stenosis or occlusion, in contrast to 15% in the IVUS group. Patients within venography group had statistically significant higher levels of VCSS at 12 months in comparison with patients within IVUS group. Our study also demonstrated a superior ability of IVUS to diagnose occlusive and stenotic lesions during followup compared with CT venography, which further expounds the crucial role of IVUS in the prognosis and follow-up of patients with venous insufficiency.

## Conclusion

IVUS is one of the most effective tools in the armamentarium of a vascular surgeon and interventionalist, especially when dealing with venous disorders. When it comes to using IVUS in patients with CVI, our study suggests that as an imaging modality, it provides more sensitive and accurate details of the lesion, aids in setting a more appropriate plan, guides the surgeon through a more precise sizing and deployment of the necessary stents, and finally, provides a better follow-up tool to detect and guide subsequent interventions, resulting in higher primary assisted and secondary patency rates. The integration of these findings, along with the clinical manifestations of the condition, might help vascular surgeons to stratify the patients to the most appropriate and effective treatment modality,

| Table 15 Association of postoperation | ative anticoagulation and | d follow-up between intra | vascular ultrasound and | venography groups |
|---------------------------------------|---------------------------|---------------------------|-------------------------|-------------------|
|                                       |                           |                           |                         |                   |

|  | Group  |            |                     |
|--|--------|------------|---------------------|
|  | IVUS   | Venography | P value             |
| Postoperative anticoagulation                            |        |            |                     |
| No   | 4      | 7          | 0.28**              |
|  | 36.4%  | 63.6%      |                     |
| Yes  | 16     | 13         |                     |
|  | 55.2%  | 44.8%      |                     |
| Duplex findings at 1 month                               |        |            |                     |
| Patent   | 20     | 20         | _                   |
|  | 50.0%  | 50.0%      |                     |
| Duplex findings at 3 months                              |        |            |                     |
| Patent   | 20     | 19         | 0.23**              |
|  | 51.3%  | 48.7%      |                     |
| Thrombosed   | 0      | 1          |                     |
|  | 0.0%   | 100.0%     |                     |
| Duplex findings at 6 months                              |        |            |                     |
| Patent   | 19     | 16         | 0.338**             |
|  | 54.3%  | 45.7%      |                     |
| Stenosed   | 0      | 1          |                     |
|  | 0.0%   | 100.0%     |                     |
| Thrombosed (fresh thrombus)                              | 1      | 2          |                     |
|  | 33.3%  | 66.7%      |                     |
| Occluded   | 0      | 1          |                     |
|  | 0.0%   | 100.0%     |                     |
| Duplex findings at 12 months                             |        |            |                     |
| Patent   | 17     | 11         | 0.154 <sup>**</sup> |
|  | 60.7%  | 39.3%      |                     |
| Stenosed   | 1      | 1          |                     |
|  | 50.0%  | 50.0%      |                     |
| Thrombosed (fresh thrombus)                              | 1      | 3          |                     |
|  | 25.0%  | 75.0%      |                     |
| Occluded   | 1      | 5          |                     |
|  | 16.7%  | 83.3%      |                     |
| TLR  |        |            |                     |
| No   | 15     | 5          | 0.002*              |
|  | 75.0%  | 25.0%      |                     |
| Yes  | 5      | 15         |                     |
|  | 25.0%  | 75.0%      |                     |
| Type of TLR  |        |            |                     |
| No   | 15     | 5          | 0.004**             |
|  | 75.0%  | 25.0%      |                     |
| Balloon dilatation                                       | 2      | 6          |                     |
|  | 25.0%  | 75.0%      |                     |
| Thrombolysis followed by balloon dilatation              | 0      | 4          |                     |
|  | 0.0%   | 100.0%     |                     |
| Thrombolysis followed by balloon dilatation and stenting | 1      | 0          |                     |
| · · · · · · · · · · · · · · · · · · ·                    | 100.0% | 0.0%       |                     |
| Failure of reintervention                                | 2      | 5          |                     |
|  | 28.6%  | 71.4%      |                     |
| Ulcer healing  |        |            |                     |
| Yes  | 3      | 5          | _                   |
|  | 37.5%  | 62.5%      |                     |

IVUS, intravascular ultrasound; TLR, target lesion revascularization. \**P*-value calculated using Chi square test. \*\**P*-value calculated using Liklihood ratio.

| Table 16 Comparing mean vales of follow-up | o data between the two groups |
|--|-------------------------------|
|--|-------------------------------|

|                                 | Group      | Ν  | Mean  | SD     | P value** | Mean difference |
|---------------------------------|------------|----|-------|--------|-----------|-----------------|
| Time to TLR in months           | IVUS       | 20 | 3.15  | 6.115  | 0.186     | -20.950         |
|                                 | Venography | 20 | 24.10 | 68.070 |           |                 |
| Ulcer healing duration (months) | IVUS       | 3  | 3.33  | 1.528  | 0.147     | -2.267          |
|                                 | Venography | 5  | 5.60  | 2.302  |           |                 |
| Postoperative creatinine        | IVUS       | 20 | 1.014 | 0.1940 | 0.000     | -0.2250         |
|                                 | Venography | 20 | 1.239 | .1565  |           |                 |


IVUS, intravascular ultrasound; TLR, target lesion revascularization. \*\*P value calculated using independent samples t test.

#### Table 17 Comparing mean number of lesions detected by intravascular ultrasound compared with venography

|  | Mean | SD    | Т     | P value** |
|--|------|-------|-------|-----------|
| Number of lesions detected by IVUS       | 2.75 | 0.786 | 6.328 | < 0.0001  |
| Number of lesions detected by venography | 1.60 | 0.754 |       |           |

IVUS, intravascular ultrasound. \*\*P value calculated using paired samples t test.

#### Figure 2



Error bar chart showing venous clinical severity scores at different time intervals.

# Table 18 Association between types of lesions detected by intravascular ultrasound and those detected by computed tomography venography at 18 months

|                   | Computed tomogra |          |          |         |
|-------------------|------------------|----------|----------|---------|
|                   | Patent           | Stenosed | Occluded | P value |
| IVUS at 18 months |                  |          |          |         |
| Patent            | 16               | 0        | 0        | 0.018** |
|                   | 100.0%           | 0.0%     | 0.0%     |         |
| Stenosed          | 2                | 1        | 0        |         |
|                   | 66.7%            | 33.3%    | 0.0%     |         |
| Occluded          | 0                | 0        | 1        |         |
|                   | 0.0%             | 0.0%     | 100.0%   |         |

IVUS, intravascular ultrasound. \*\*P value calculated using likelihood ratio.

plan, and execution. Newer and smaller caliber IVUS fibers along with better diagnostic accuracy and range are in dire need to make the use of IVUS more feasible and less invasive, and eventually overcome the major inconvenience associated with its use (Fig. 2 and Table 18).

# Financial support and sponsorship Nil.

#### **Conflicts of interest**

There are no conflicts of interest.

#### References

- 1 Waheed SM, Kudaravalli P, Hotwagner DT. Deep Vein Thrombosis. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih. gov/books/NBK507708/
- 2 Rabinovich A, Kahn SR. The postthrombotic syndrome: current evidence and future challenges. J Thromb Haemost 2017; 15:230–241.
- 3 Engelberger RP, Fahrni J, Willenberg T, Baumann F, Spirk D, Diehm N, et al. Fixed low-dose ultrasound- assisted catheter-directed thrombolysis followed by routine stenting of residual stenosis for acute ilio-femoral deep-vein thrombosis. Thromb Haemost 2014; 111:1153–1160.

- 4 Lau I, Png CYM, Eswarappa M, Miller M, Kumar S, Tadros R, et al. Defining the utility of anteroposterior venography in the diagnosis of venous iliofemoral obstruction. J Vasc Surg Venous Lymphat Disord 2019; 7:514–521.
- 5 Gagne PJ, Gasparis A, Black S, Thorpe P, Passman M, Vedantham S, et al. Analysis of threshold stenosis by multiplanar venogram and intravascular ultrasound examination for predicting clinical improvement after iliofemoral vein stenting in the VIDIO trial. J Vasc Surg Venous Lymphat Disord 2018; 6:48–56.
- 6 Neglén P, Raju S. Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome. J Endovasc Ther 2000; 7:76–91.
- 7 Neglén P, Tackett TP, Raju S. Venous stenting across the inguinal ligament. J Vasc Surg 2008; 48:1255–1261.
- 8 Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg 2010; 52:1387–1396.
- 9 Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40:1248–1252.
- 10 Gagne PJ, Tahara RW, Fastabend CP, Dzieciuchowicz L, Marston W, Vedantham S, et al. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. J Vasc Surg Venous Lymphat Disord 2017; 5: 678–687.
- 11 Raju S, Davis M. Anomalous features of iliac vein stenosis that affect diagnosis and treatment. J Vasc Surg Venous Lymphat Disord 2014; 2:260–267.